Nilho (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Nilho, is a combined estrogen‑progestogen contraceptive presented as a vaginal contraceptive ring for vaginal use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus.

GNH USA supplies Nilho as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nilho, a combined estrogen‑progestogen contraceptive, is used within the hormonal contraception family to prevent unintended pregnancy.

- Contraception: provides reliable, reversible prevention of pregnancy for women of child‑bearing potential. - Family planning: enables controlled fertility management in partnership with healthcare providers. - Ovulation suppression: inhibits gonadotropin release to stop the release of an egg each cycle.

Common side effects are generally mild and transient, reflecting the hormonal activity of the ring.

Common Side Effects: - Vaginal irritation or discharge: mild irritation at the insertion site. - Headache: occasional tension‑type headaches. - Nausea: mild stomach upset, often transient. - Breast tenderness: temporary swelling or soreness. - Mood changes: mild fluctuations in mood or irritability. - Spotting: irregular bleeding between periods.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Hepatic adenoma: rare benign liver tumor. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hypertension: significant increase in blood pressure. - Visual disturbances: sudden loss of vision or blurred sight. - Ectopic pregnancy: implantation outside the uterus if contraception fails.

Before prescribing Nilho, clinicians should evaluate individual risk factors and counsel patients on proper use.

- Assess thrombotic risk: review personal and family history of clotting disorders. - Screen for liver disease: avoid use in active hepatic impairment. - Evaluate cardiovascular status: consider hypertension or smoking history. - Counsel on smoking cessation: especially for women over 35 years. - Review medication history: identify drugs that may reduce efficacy. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and direct sunlight.

Nilho may interact with other medicines that affect hormone metabolism or clotting pathways.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce contraceptive effectiveness. - Anticoagulants (e.g., warfarin): hormonal changes can alter INR stability. - Selective serotonin reuptake inhibitors (high dose): may increase risk of serotonin syndrome when combined with certain hormonal agents.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase hormone levels, raising side‑effect risk. - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly diminish contraceptive efficacy. - Herbal supplements (e.g., St. John's wort): can modestly lower hormone concentrations.